3MACLEOD S,PETERSON R,WANG Y,et al.Challenges in international pediatric pharmacology:a milestone meeting in Shanghai[J].Pediatric drugs,2007,9(4):215-218.
5WANG L,ZAO D Y,ZHANG Z H,et al.Trial of antiepilep- sirine(AES)in children with epilepsy[J].Brain & development,1999,21:3640.
二级参考文献16
1Shirkey H. Therapeutic orphans. J Pediatrics, 1968,72 : 119-120.
2Gazarian M. Why are children still therapeutic orphans? Aust Prescr,2003 ,26 :122-123.
3Stoyanova-Beninska VV, Wohlfarth T, Isaac M, et al. The EU Paediatric regulation: effects on pediatric psychopharmacology in Europe. Eurpean Neurosychopharmacolol, 2011,21:565-570.
4Choonara I. Regulation of drugs for children in Europe. BMJ, 2007, 335: 1221-1222.
5Pasquali SK, Lam WK, Chiswell K, et al. Status of the pediatric clinical trials enterprise: an analysis of the US Clinical Trials. gov registry. Pediatrics, 2012,130 : e1269-1277.
6Shah SS, Hall M,Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med, 2007,161:282-290.
7Choonara I, Dewit O, Harrop E, et al. Training in paediatric clinical pharmacology in the UK. Br J Clin Pharmaeol, 2004, 58:217-218.
8MaeLeod S, Peterson R, Wang Y, et al. Challenges in international pediatric pharmacology: a milestone meeting in Shanghai. Paediatr Drugs,2007, 9 : 215-218.
9Buck ML. The FDA Modernization Act of 1997: Impact on pediatric medicine . Pediatri Pharm, 2000,6:12.
10Hoppu K. Can we get the necessary clinical trails in children and avoid the unnecessary ones? Eur J Clin Pharmacol, 2009, 65:747-748.
